

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



## **Jacobson Pharma Corporation Limited**

## **雅各臣科研製藥有限公司**

(Incorporated under the laws of the Cayman Islands with limited liability)

Stock Code : 2633

### **RESIGNATION OF INDEPENDENT NON-EXECUTIVE DIRECTOR, CHAIRMAN OF NOMINATION COMMITTEE AND MEMBER OF AUDIT COMMITTEE AND APPOINTMENT OF INDEPENDENT NON-EXECUTIVE DIRECTOR, CHAIRMAN OF NOMINATION COMMITTEE AND MEMBER OF AUDIT COMMITTEE**

The board (the “**Board**”) of directors (the “**Directors**”) of Jacobson Pharma Corporation Limited (the “**Company**”, together with its subsidiaries, the “**Group**”), hereby announces that Professor Chow Hee Lum, Albert (“**Professor Chow**”) has tendered his resignation as an independent non-executive Director, the chairman of nomination committee and a member of audit committee of the Company, and a member of scientific advisory committee of the Company with effect from 1 December 2017 due to his other engagements which require more of his time and attention. Professor Chow has confirmed that he has no disagreement with the Board of the Company or any of the committees that he has served on; and there are no matters that need to be brought to the attention of the holders of securities of the Company in relation to his resignation.

The Board wishes to take this opportunity to express its appreciation to Professor Chow for his invaluable contribution to the Company during his tenure of office.

The Board of the Company is also pleased to announce that Professor Wong Chi Kei, Ian (“**Professor Wong**”) has been appointed as an independent non-executive Director of the Company, and the chairman of nomination committee and a member of audit committee of the Company with effect from 1 December 2017.

Professor Wong, aged 50, is at present a member of the scientific advisory committee of the Company since 2016.

Professor Wong is jointly appointed by the University of Hong Kong and UCL School of Pharmacy in London. Professor Wong is the Co-Director of the Centre for Safe Medication Practice and Research at the University of Hong Kong and Head of Research Department of Practice and Policy at UCL School of Pharmacy.

Prior to his current appointment, Professor Wong was a member of the Pharmacy and Poisons Board of Hong Kong between 2012 and 2014. Professor Wong was the Head of the Department of Pharmacology and Pharmacy of the University of Hong Kong between 2011 and 2015, the Founding Director of the Centre for Paediatric Pharmacy Research between 2002 and 2011, at The School of Pharmacy, UCL Institute of Child Health, University of London and Great Ormond Street Hospital for Children.

A recipient of a UK Department of Health Public Health Career Scientist Award in 2002, Professor Wong is the only pharmacist to date to have received such an award in the UK. He also received the Chemist and Druggist's Pharmacy Practice Research Medal in 2004 for his research in paediatric medicines. In recognition of his work in paediatric medicines research, Professor Wong was awarded an Honorary Fellowship of the Royal College of Paediatrics and Child Health in 2011, and Fellowship of the Royal Pharmaceutical Society in 2012.

Professor Wong qualified as a pharmacist in the UK in 1992 and in Hong Kong in 1993. Professor Wong worked at the former Medicines Control Agency (Regulatory Authority) between 1992 and 1993. His research career began when he took up a research pharmacist post at the David Lewis Centre for Epilepsy to investigate the safety of new antiepileptic drugs between 1994 and 1997. Professor Wong received his PhD from Manchester Medical School in 1998 for his work at the David Lewis Centre. Thereafter, he took up a Lecturer in Pharmacy Practice post at the University of Bradford in 1997, and became Senior Lecturer in 2001.

In association with UCL School of Pharmacy, UCL Institute Child Health, Great Ormond Street Children's Hospital and investors, Professor Wong set up Therakind Ltd in 2007. Therakind Ltd is a private European pharmaceutical company specialising in research and development of medicines for children.

Professor Wong has entered into a letter of appointment with the Company at a fee of HK\$208,000 per annum for a term of three (3) years commencing from 1 December 2017, which can be terminated by either party giving to the other party not less than one month's notice in writing. The director's fee of Professor Wong was determined by the Board, upon taking into consideration of the recommendation by the remuneration committee with reference to the prevailing market benchmark as well as his roles and duties of the Group.

Pursuant to the articles of association of the Company and the Corporate Governance Code as set out in Appendix 14 to the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the "**Listing Rules**"), Professor Wong will hold office until the forthcoming general meeting of the Company and will be subject to the retirement by rotation and re-election at that meeting.

Saved as disclosed above, Professor Wong has not held other positions with the Company or any of its subsidiaries and has not held any other directorships in any listed public companies in the last three years. Furthermore, Professor Wong does not have any relationship with any directors, senior management, substantial shareholders or controlling shareholders of the Company.

As at the date of this announcement, Professor Wong does not have any interest or deem to be interested in shares or underlying shares of the Company within the meaning of Part XV of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

Save as disclosed above, there is no other information that is required to be disclosed under Rules 13.51(2)(h) to 13.51(2)(v) of the Listing Rules and there are no other matters in relation to the appointment of Professor Wong that need to be brought to the attention of the shareholders of the Company and the Stock Exchange.

The Board would like to express its warmest welcome to Professor Wong for joining the Board.

By Order of the Board  
**Jacobson Pharma Corporation Limited**  
**Wu Lai King**  
*Company Secretary*

Hong Kong, 22 November 2017

*As at the date of this announcement, the Board comprises Mr. Sum Kwong Yip, Derek (also as Chairman and Chief Executive Officer), Mr. Yim Chun Leung and Ms. Pun Yue Wai as executive Directors, Professor Lam Sing Kwong, Simon as non-executive Director, and Dr. Lam Kwing Tong, Alan, Professor Chow Hee Lum, Albert and Mr. Young Chun Man, Kenneth as independent non-executive Directors.*